Canopy Growth (CGC -1.95%) slipped to $0.92, a 1.95% decline, as investors realized the firm will not profit from the United States’ federal marijuana rescheduling.
A slow progression for pot?
The United States has moved to re‑classify marijuana from a Schedule I narcotic to a Schedule III drug, the same category as acetaminophen, clearing a path for research and commerce while keeping the product under federal oversight.
Canopy Growth isn’t likely to benefit from rescheduling
Canopy Growth remains a Canada‑focused and Europe‑focused producer, with its core business anchored outside the United States.
The company holds a minority stake in Canopy USA, a platform designed to help U.S. operators enter the market, but the deal is structured to avoid direct involvement in U.S. cannabis activities, according to the firm’s securities filing.
Because the rescheduling emphasizes medical use and research, and Canopy USA concentrates on recreational sales, the change offers limited upside for the Canadian producer.
Canopy Growth isn’t in the right place at the right time
Heavy investment in Canadian medical marijuana, bolstered by the recent acquisition of MTL Cannabis, left the company with minimal exposure to the U.S. market.
Management chose to limit direct control over U.S. operations to comply with federal law, a strategic move that now dampens any potential windfall from rescheduling.
Analysts note that while the rescheduling improves the industry’s overall outlook, Canopy Growth’s lack of U.S. foothold and its focus on medical markets mean the stock is unlikely to surge despite the policy shift.
Market Cap $397M
Day’s Range $0.91 – $0.95
52‑week Range $0.84 – $2.38
Volume 1.6M
Avg Vol 3.7M
Gross Margin 18.25%
